[Expert consensus on chloroquine phosphate for the treatment of novel coronavirus pneumonia].
Identifieur interne : 000F96 ( Ncbi/Merge ); précédent : 000F95; suivant : 000F97[Expert consensus on chloroquine phosphate for the treatment of novel coronavirus pneumonia].
Auteurs :Source :
- Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases [ 1001-0939 ] ; 2020.
Descripteurs français
- KwdFr :
- Anti-inflammatoires non stéroïdiens (administration et posologie), Calendrier d'administration des médicaments, Chine, Chloroquine (administration et posologie), Chloroquine (analogues et dérivés), Consensus, Durée du séjour, Guides de bonnes pratiques cliniques comme sujet, Humains, Infections à coronavirus (), Pneumopathie virale (), Pneumopathie virale (traitement médicamenteux), Pneumopathie virale (étiologie).
- MESH :
- administration et posologie : Anti-inflammatoires non stéroïdiens, Chloroquine.
- analogues et dérivés : Chloroquine.
- traitement médicamenteux : Pneumopathie virale.
- étiologie : Pneumopathie virale.
- Calendrier d'administration des médicaments, Chine, Consensus, Durée du séjour, Guides de bonnes pratiques cliniques comme sujet, Humains, Infections à coronavirus, Pneumopathie virale.
- Wicri :
- geographic : République populaire de Chine.
English descriptors
- KwdEn :
- Anti-Inflammatory Agents, Non-Steroidal (administration & dosage), China, Chloroquine (administration & dosage), Chloroquine (analogs & derivatives), Consensus, Coronavirus Infections (complications), Drug Administration Schedule, Humans, Length of Stay, Pneumonia, Viral (complications), Pneumonia, Viral (drug therapy), Pneumonia, Viral (etiology), Practice Guidelines as Topic.
- MESH :
- chemical , administration & dosage : Anti-Inflammatory Agents, Non-Steroidal, Chloroquine.
- chemical , analogs & derivatives : Chloroquine.
- geographic : China.
- complications : Coronavirus Infections, Pneumonia, Viral.
- drug therapy : Pneumonia, Viral.
- etiology : Pneumonia, Viral.
- Consensus, Drug Administration Schedule, Humans, Length of Stay, Practice Guidelines as Topic.
Abstract
At the end of December 2019, a novel coronavirus (COVID-19) caused an outbreak in Wuhan, and has quickly spread to all provinces in China and 26 other countries around the world, leading to a serious situation for epidemic prevention. So far, there is still no specific medicine. Previous studies have shown that chloroquine phosphate (chloroquine) had a wide range of antiviral effects, including anti-coronavirus. Here we found that treating the patients diagnosed as novel coronavirus pneumonia with chloroquine might improve the success rate of treatment, shorten hospital stay and improve patient outcome. In order to guide and regulate the use of chloroquine in patients with novel coronavirus pneumonia, the multicenter collaboration group of Department of Science and Technology of Guangdong Province and Health Commission of Guangdong Province for chloroquine in the treatment of novel coronavirus pneumonia developed this expert consensus after extensive discussion. It recommended chloroquine phosphate tablet, 500mg twice per day for 10 days for patients diagnosed as mild, moderate and severe cases of novel coronavirus pneumonia and without contraindications to chloroquine.
DOI: 10.3760/cma.j.issn.1001-0939.2020.03.009
PubMed: 32164085
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 000595
- to stream PubMed, to step Curation: 000595
- to stream PubMed, to step Checkpoint: 000072
Links to Exploration step
pubmed:32164085Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">[Expert consensus on chloroquine phosphate for the treatment of novel coronavirus pneumonia].</title></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2020">2020</date><idno type="RBID">pubmed:32164085</idno><idno type="pmid">32164085</idno><idno type="doi">10.3760/cma.j.issn.1001-0939.2020.03.009</idno><idno type="wicri:Area/PubMed/Corpus">000595</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000595</idno><idno type="wicri:Area/PubMed/Curation">000595</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000595</idno><idno type="wicri:Area/PubMed/Checkpoint">000072</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000072</idno><idno type="wicri:Area/Ncbi/Merge">000F96</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">[Expert consensus on chloroquine phosphate for the treatment of novel coronavirus pneumonia].</title></analytic><series><title level="j">Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases</title><idno type="ISSN">1001-0939</idno><imprint><date when="2020" type="published">2020</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Anti-Inflammatory Agents, Non-Steroidal (administration & dosage)</term><term>China</term><term>Chloroquine (administration & dosage)</term><term>Chloroquine (analogs & derivatives)</term><term>Consensus</term><term>Coronavirus Infections (complications)</term><term>Drug Administration Schedule</term><term>Humans</term><term>Length of Stay</term><term>Pneumonia, Viral (complications)</term><term>Pneumonia, Viral (drug therapy)</term><term>Pneumonia, Viral (etiology)</term><term>Practice Guidelines as Topic</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Anti-inflammatoires non stéroïdiens (administration et posologie)</term><term>Calendrier d'administration des médicaments</term><term>Chine</term><term>Chloroquine (administration et posologie)</term><term>Chloroquine (analogues et dérivés)</term><term>Consensus</term><term>Durée du séjour</term><term>Guides de bonnes pratiques cliniques comme sujet</term><term>Humains</term><term>Infections à coronavirus ()</term><term>Pneumopathie virale ()</term><term>Pneumopathie virale (traitement médicamenteux)</term><term>Pneumopathie virale (étiologie)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Anti-Inflammatory Agents, Non-Steroidal</term><term>Chloroquine</term></keywords><keywords scheme="MESH" type="chemical" qualifier="analogs & derivatives" xml:lang="en"><term>Chloroquine</term></keywords><keywords scheme="MESH" type="geographic" xml:lang="en"><term>China</term></keywords><keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Anti-inflammatoires non stéroïdiens</term><term>Chloroquine</term></keywords><keywords scheme="MESH" qualifier="analogues et dérivés" xml:lang="fr"><term>Chloroquine</term></keywords><keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Coronavirus Infections</term><term>Pneumonia, Viral</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Pneumonia, Viral</term></keywords><keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Pneumonia, Viral</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Pneumopathie virale</term></keywords><keywords scheme="MESH" qualifier="étiologie" xml:lang="fr"><term>Pneumopathie virale</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Consensus</term><term>Drug Administration Schedule</term><term>Humans</term><term>Length of Stay</term><term>Practice Guidelines as Topic</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Calendrier d'administration des médicaments</term><term>Chine</term><term>Consensus</term><term>Durée du séjour</term><term>Guides de bonnes pratiques cliniques comme sujet</term><term>Humains</term><term>Infections à coronavirus</term><term>Pneumopathie virale</term></keywords><keywords scheme="Wicri" type="geographic" xml:lang="fr"><term>République populaire de Chine</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">At the end of December 2019, a novel coronavirus (COVID-19) caused an outbreak in Wuhan, and has quickly spread to all provinces in China and 26 other countries around the world, leading to a serious situation for epidemic prevention. So far, there is still no specific medicine. Previous studies have shown that chloroquine phosphate (chloroquine) had a wide range of antiviral effects, including anti-coronavirus. Here we found that treating the patients diagnosed as novel coronavirus pneumonia with chloroquine might improve the success rate of treatment, shorten hospital stay and improve patient outcome. In order to guide and regulate the use of chloroquine in patients with novel coronavirus pneumonia, the multicenter collaboration group of Department of Science and Technology of Guangdong Province and Health Commission of Guangdong Province for chloroquine in the treatment of novel coronavirus pneumonia developed this expert consensus after extensive discussion. It recommended chloroquine phosphate tablet, 500mg twice per day for 10 days for patients diagnosed as mild, moderate and severe cases of novel coronavirus pneumonia and without contraindications to chloroquine.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" IndexingMethod="Curated" Owner="NLM"><PMID Version="1">32164085</PMID><DateCompleted><Year>2020</Year><Month>03</Month><Day>20</Day></DateCompleted><DateRevised><Year>2020</Year><Month>03</Month><Day>25</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1001-0939</ISSN><JournalIssue CitedMedium="Print"><Volume>43</Volume><Issue>3</Issue><PubDate><Year>2020</Year><Month>Mar</Month><Day>12</Day></PubDate></JournalIssue><Title>Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases</Title><ISOAbbreviation>Zhonghua Jie He He Hu Xi Za Zhi</ISOAbbreviation></Journal><ArticleTitle>[Expert consensus on chloroquine phosphate for the treatment of novel coronavirus pneumonia].</ArticleTitle><Pagination><MedlinePgn>185-188</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.3760/cma.j.issn.1001-0939.2020.03.009</ELocationID><Abstract><AbstractText>At the end of December 2019, a novel coronavirus (COVID-19) caused an outbreak in Wuhan, and has quickly spread to all provinces in China and 26 other countries around the world, leading to a serious situation for epidemic prevention. So far, there is still no specific medicine. Previous studies have shown that chloroquine phosphate (chloroquine) had a wide range of antiviral effects, including anti-coronavirus. Here we found that treating the patients diagnosed as novel coronavirus pneumonia with chloroquine might improve the success rate of treatment, shorten hospital stay and improve patient outcome. In order to guide and regulate the use of chloroquine in patients with novel coronavirus pneumonia, the multicenter collaboration group of Department of Science and Technology of Guangdong Province and Health Commission of Guangdong Province for chloroquine in the treatment of novel coronavirus pneumonia developed this expert consensus after extensive discussion. It recommended chloroquine phosphate tablet, 500mg twice per day for 10 days for patients diagnosed as mild, moderate and severe cases of novel coronavirus pneumonia and without contraindications to chloroquine.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><CollectiveName>multicenter collaboration group of Department of Science and Technology of Guangdong Province and Health Commission of Guangdong Province for chloroquine in the treatment of novel coronavirus pneumonia</CollectiveName></Author></AuthorList><Language>chi</Language><GrantList CompleteYN="Y"><Grant><GrantID>2020B111113001</GrantID><Agency>Emergency program for major public health event of Ministry of Science and Technology, Department of Science and Technology of Guangdong Province</Agency><Country></Country></Grant><Grant><GrantID>2020GZR110106003</GrantID><Agency>Guangzhou Regenerative Medicine and Health Guangdong Laboratory: Evaluation of clinical efficacy of chloroquine on 2019 novel coronavirus pneumonia</Agency><Country></Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>China</Country><MedlineTA>Zhonghua Jie He He Hu Xi Za Zhi</MedlineTA><NlmUniqueID>8712226</NlmUniqueID><ISSNLinking>1001-0939</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000894">Anti-Inflammatory Agents, Non-Steroidal</NameOfSubstance></Chemical><Chemical><RegistryNumber>6E17K3343P</RegistryNumber><NameOfSubstance UI="C023676">chloroquine diphosphate</NameOfSubstance></Chemical><Chemical><RegistryNumber>886U3H6UFF</RegistryNumber><NameOfSubstance UI="D002738">Chloroquine</NameOfSubstance></Chemical></ChemicalList><SupplMeshList><SupplMeshName Type="Disease" UI="C000657245">COVID-19</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000894" MajorTopicYN="N">Anti-Inflammatory Agents, Non-Steroidal</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration & dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002681" MajorTopicYN="N" Type="Geographic">China</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002738" MajorTopicYN="N">Chloroquine</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName><QualifierName UI="Q000031" MajorTopicYN="Y">analogs & derivatives</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D032921" MajorTopicYN="N">Consensus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018352" MajorTopicYN="N">Coronavirus Infections</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004334" MajorTopicYN="N">Drug Administration Schedule</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007902" MajorTopicYN="N">Length of Stay</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011024" MajorTopicYN="N">Pneumonia, Viral</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017410" MajorTopicYN="N">Practice Guidelines as Topic</DescriptorName></MeshHeading></MeshHeadingList><OtherAbstract Type="Publisher" Language="chi"><AbstractText>自2019年12月，武汉暴发了一种新型冠状病毒（COVID-19）感染，迅速蔓延至我国各省市及全球26个国家，防疫形势十分严峻。但是目前尚无特效药物。磷酸氯喹（简称氯喹）具有广泛抗病毒及抗冠状病毒的作用，临床研究结果显示氯喹或可提高新型冠状病毒肺炎患者的救治成功率、缩短住院时间及改善预后。为指引并规范氯喹在新型冠状病毒肺炎中的使用，广东省科技厅、广东省卫生健康委氯喹治疗新冠状病毒肺炎多中心协作组经充分讨论后，制定本专家共识,对确诊为新型冠状病毒肺炎轻型、普通型和重型患者，排除氯喹禁忌证后，可以使用磷酸氯喹片每次500 mg，2次/d，疗程10 d。.</AbstractText></OtherAbstract><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Chloroquine</Keyword><Keyword MajorTopicYN="N">Novel coronavirus pneumonia</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>3</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>3</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>3</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32164085</ArticleId><ArticleId IdType="doi">10.3760/cma.j.issn.1001-0939.2020.03.009</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list></list><tree></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/CovidV2/Data/Ncbi/Merge
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000F96 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd -nk 000F96 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= CovidV2
|flux= Ncbi
|étape= Merge
|type= RBID
|clé= pubmed:32164085
|texte= [Expert consensus on chloroquine phosphate for the treatment of novel coronavirus pneumonia].
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/RBID.i -Sk "pubmed:32164085" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd \
| NlmPubMed2Wicri -a CovidV2
| This area was generated with Dilib version V0.6.33. |  |